Jubilant Ingrevia reported consolidated net profit of ₹105.82 crore for the quarter ended 30 June 2026, up about 40.9% year over year. Revenue from operations rose about 25% to ₹1,300.27 crore, with EBITDA around ₹199 crore and the margin expanding to about 15.45%. Profit before tax stood at ₹140.86 crore, and total quarterly income reached roughly ₹1,310 crore. The results were driven by strong performance across its Speciality Chemicals, Nutrition & Health Solutions, and Chemical Intermediates segments, aided by improved cost management. Shares rose around 3.6% on the news, signaling positive investor sentiment for Jubilant Ingrevia. The company noted no exceptional items in the period, and results were supported by continued execution and capacity expansion initiatives.